HCP1701

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

DyslipidemiasHealthyHypertension

Phase 1

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

CompletedNCT04322266

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-12-21End: 2019-02-13Updated: 2020-03-26

Phase 3

A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

CompletedNCT04074551

Hanmi Pharmaceutical Company LimitedDyslipidemias, Hypertension

Start: 2019-07-16End: 2020-03-17Updated: 2020-11-30

Related Papers

Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants.

2024-05-22

A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia

American Journal of Cardiovascular Drugs2023-07-017 citations